Pre- and Post-Surgery Treatments in Rectal Cancer: A Long-Term Single-Centre Experience

Özyurt, Hazan; Özgen, Zerrin; Gemici, Cengiz; Yaprak, Gökhan

doi:10.3747/co.24.3229

Cited by 3 publications

(4 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall local recurrence, which is a surrogate measure of the efficacy of the local treatment, was 3.3% and closely reflects previously reported rates. 16,17 Although the German rectal cancer study had reported local recurrence rates of approximately 6%, 1 subsequent studies showed fewer local recurrences, 2,12,23 and a similar trend was seen in our study group as well (3.2% and 3.5% in the SD and HD groups, p = 0.8). The incidence of distant recurrence was also similar in the 2 radiation dose groups (17.4% in the SD group and 19.4% in the HD group; p = 0.36).…”

Section: Discussionsupporting

confidence: 85%

“…8 Although some studies have reported an increased pathological response with dose escalation, others have been more cautious about this increased pathological response. [9][10][11][12] However, almost all of the studies have reported observing significantly improved benefits with radiation doses beyond 4500 cGy. In fact, a dose-response model derived from patients treated with external beam radiation and brachytherapy boost showed a dose response with increased pCR at higher doses.…”

mentioning

confidence: 99%

See 1 more Smart Citation

More Is Not Better When It Comes to Treating Rectal Cancer With Multimodal Chemoradiation Beyond the Standard Radiation Dose of 5040 cGy

Abraham¹,

Joseph

Ghosh

et al. 2022

Diseases of the Colon &Amp; Rectum

View full text Add to dashboard Cite

BACKGROUND:Radiation dose schedules for neoadjuvant chemoradiation for rectal cancers differ, with the most common dose schedule using 5040 cGy in 28 fractions. OBJECTIVES:The aim of this retrospective study was to assess the benefit of higher radiation doses beyond 5040 cGy in the context of pathological response and follow-up events. SETTING:The database from a provincial tertiary cancer center in Canada was the source of information for this study.PATIENTS: Included in this study were 508 consecutive patients with rectal cancer with locally advanced disease (clinical T3/T4 or N1/N2) who received neoadjuvant chemoradiation followed by surgery. Of the 508 patients, 281 received the standard radiation dose of 4500 to 5040 cGy and 227 received a dose >5040 cGy. MAIN OUTCOME MEASURE:The postsurgical pathology, late toxicities, and follow-up outcomes were analyzed. The outcomes were evaluated in relation to the dose of radiation received.RESULTS: Data regarding the clinical outcomes were comparable between the 4500 to 5040 cGy and >5040 cGy radiation groups with pathological complete response rates of 20.9% and 15.4% (p = 0.104); distant recurrence rates of 17.4% and 19.4% (p = 0.36); local recurrence rates of 3.2% and 3.5% (p = 0.36); and the median overall survival rates of 61 and 60.5 months (p = 0.8). No statistically significant correlation of improvement in outcomes was noted with radiation doses beyond 5040 cGy.LIMITATIONS: This is a retrospective study. CONCLUSION:Our study showed that dose escalation beyond the standard dose of 4500 to 5040cGy failed to achieve meaningful clinical outcomes. See Video Abstract at http://links.lww.com/DCR/B633.

show abstract

Section: Discussionsupporting

confidence: 85%

mentioning

confidence: 99%

More Is Not Better When It Comes to Treating Rectal Cancer With Multimodal Chemoradiation Beyond the Standard Radiation Dose of 5040 cGy

Abraham¹,

Joseph

Ghosh

et al. 2022

Diseases of the Colon &Amp; Rectum

View full text Add to dashboard Cite

show abstract

“…The standard treatment for locally advanced rectal cancer (LARC) is preoperative chemoradiotherapy followed by surgical resection with total mesorectal excision (TME) [2,3]. Especially for patients with mid-low rectal cancer and T3 or T4 stage, preoperative chemoradiotherapy can effectively reduce the tumor volume, increase sphincter preservation, decrease local recurrence, and have long-term survival benefits [4]. However, the therapeutic effect of preoperative chemoradiotherapy on patients with rectal cancer varies significantly among individuals, with only a few patients (9-37%) achieving a pathological complete response (pCR) after treatment [5].…”

Section: Introductionmentioning

confidence: 99%

Artemis as Predictive Biomarker of Responsiveness to Preoperative Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer

Liu,

Huang,

Shan

et al. 2024

Current Oncology

View full text Add to dashboard Cite

The aim of this study was to identify Artemis as a predictive biomarker for guiding preoperative chemoradiotherapy in locally advanced rectal cancer. The resection specimens were collected from 50 patients with rectal cancer who underwent preoperative chemoradiotherapy. Artemis expression in biopsy tissues was evaluated using immunohistochemical staining according to the percentage of positively stained cells combined with staining intensity. Among the 50 patients, 36 (72%) had a weakly positive Artemis protein expression, 10 (20%) had a moderately positive expression, and 4 (8%) showed a strongly positive expression. The criteria of magnetic resonance imaging tumor regression grade (mrTRG) and pathological rectal cancer regression grade (RCRG) were used to assess the tumor response to chemoradiotherapy. Correlation analysis shows that there is a significant negative correlation between high Artemis immunoscore and treatment response (r = −0.532, p < 0.001). The results imply that high Artemis expression was associated with poor treatment response. Our study suggested a potential role of Artemis as a predictive biomarker of the tumor response to preoperative chemoradiotherapy in patients with locally advanced rectal cancer.

show abstract

“…Colorectal cancer, including rectal cancer, is the third most prevalent malignancy worldwide and a leading cause of cancer-related deaths in the developed world (1). Synchronous distant metastases are diagnosed in approximately 15-20% of rectal cancer patients, most commonly involving the liver (2).…”

Section: Introductionmentioning

confidence: 99%

Cryopreserved biopsy tissues of rectal cancer liver metastasis for assessment of anticancer drug response in�vitro and in�vivo

et al. 2019

View full text Add to dashboard Cite

Living tumors are of great scientific value for clinical medicine and basic research, especially for drug testing. An increasing number of drug tests fail due to the use of imperfect models. The aim of the present study was to develop a novel method combining vitrification-based cryopreservation of tumor biopsies and precision-cut slice cultivation for the assessment of anticancer drug responses. Biological characteristics of rectal cancer liver metastasis biopsies could be retained by vitrification-based cryopreservation. The patient-derived xenograft models were successfully established using both fresh and warmed biopsy tissues. Precision-cut slicing provided a similar three-dimensional architecture and heterogeneity to the original tumor. The positive drug responses in the xenograft model were consistent with those in precision-cut slice cultures in vitro. The present study demonstrated that live tumor biopsies could be preserved using vitrification-based cryopreservation. The warmed tissues developed xenograft tumors, which were also useful for either in vivo or in vitro anticancer drug testing. Precision-cut slices derived from the warmed tissues provided an efficient tool to assess anticancer drug response in vitro.

show abstract

Pre- and Post-Surgery Treatments in Rectal Cancer: A Long-Term Single-Centre Experience

Abstract: Background Our study evaluated long-term survival outcomes in rectal cancer patients treated with preoperative

Cited by 3 publications

References 49 publications

More Is Not Better When It Comes to Treating Rectal Cancer With Multimodal Chemoradiation Beyond the Standard Radiation Dose of 5040 cGy

More Is Not Better When It Comes to Treating Rectal Cancer With Multimodal Chemoradiation Beyond the Standard Radiation Dose of 5040 cGy

Artemis as Predictive Biomarker of Responsiveness to Preoperative Chemoradiotherapy in Patients with Locally Advanced Rectal Cancer

Cryopreserved biopsy tissues of rectal cancer liver metastasis for assessment of anticancer drug response in�vitro and in�vivo

Contact Info

Product

Resources

About